• Pfizer reported third-quarter 2026 adjusted diluted EPS of $0.87, while revenue declined year over year to $16.6 billion.
• ELREXFIO delivered a statistically significant progression-free survival benefit in Phase 3 multiple myeloma testing; global regulatory submissions are planned.
• Full-year 2026 guidance rose to $62 billion–$64 billion for revenue and $2.95–$3.05 for adjusted diluted EPS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.